| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥36.3B | ¥310.5B | -88.3% |
| Operating Income | ¥-49.2B | ¥-10.1B | -388.0% |
| Ordinary Income | ¥-114.1B | ¥-32.4B | -252.3% |
| Net Income | ¥-124.7B | ¥-32.6B | -281.8% |
| ROE | -30.5% | -6.6% | - |
FY2026 results show severe operational distress: Revenue ¥3.63B (YoY -88.3%), Operating Loss ¥4.92B (YoY -388.0%), Ordinary Loss ¥11.41B (YoY -252.3%), Net Loss ¥12.47B (YoY -281.8%). The dramatic revenue collapse from ¥31.05B to ¥3.63B triggered negative gross profit of ¥3.97B (gross margin -109.5%), reflecting fundamental business model stress. Equity method investment losses of ¥6.33B and extraordinary impairment of ¥0.58B compounded the deterioration. Despite net losses, Operating CF remained positive at ¥0.75B, though significantly down from ¥4.01B YoY (-81.4%). Cash position weakened to ¥0.27B versus ¥6.67B short-term debt, creating acute liquidity pressure with current ratio at 45.1%. Total Assets declined to ¥52.00B from ¥60.08B, driven by investment securities concentration at ¥34.62B (66.6% of total assets). The company projects FY2027 revenue recovery to ¥6.00B (+65.2% YoY) but anticipates continued losses with Operating Loss ¥2.40B and Net Loss ¥4.40B.
Revenue contracted 88.3% YoY from ¥31.05B to ¥3.63B, driven by structural demand shifts in the Separator segment which declined to ¥2.21B (60.9% of total revenue) from prior dominance. The Ion Exchange Membrane segment generated ¥1.42B in revenue. Customer concentration shifted dramatically, with prior year's Samsung SDI Group revenue of ¥28.45B replaced by W-SCOPE CHUNGJU PLANT at ¥1.87B and POSCO Group at ¥1.40B, indicating fundamental market repositioning. Cost structure deteriorated as COGS of ¥7.61B exceeded revenue, creating negative gross profit of ¥3.97B. SG&A expenses of ¥0.95B (26.0% of revenue) remained relatively fixed, contributing to operating loss of ¥4.92B (operating margin -135.5%). Non-operating items severely impacted results: Equity method losses of ¥6.33B (representing investments in affiliates experiencing distress) and foreign exchange losses of ¥0.19B drove total non-operating expenses to ¥6.83B against non-operating income of ¥0.34B (including FX gains of ¥1.01B), resulting in ordinary loss of ¥11.41B. The gap between operating loss (¥4.92B) and ordinary loss (¥11.41B) of ¥6.49B is primarily attributable to equity method investment losses. Extraordinary items included impairment loss of ¥0.58B on Separator segment assets and loss on sale of subsidiary stock of ¥0.47B, bringing total extraordinary losses to ¥1.05B. Income tax benefit of minimal ¥0.01B resulted in net loss attributable to owners of ¥12.47B. This represents a revenue down/profit down pattern with structural business model challenges evident in negative gross margins and persistent equity method losses.
Separator segment generated revenue of ¥2.21B with operating loss of ¥4.48B, representing a margin of -202.4%. This core business (60.9% of total revenue) faces acute profitability challenges with revenue unable to cover direct costs. Ion Exchange Membrane segment delivered revenue of ¥1.42B with operating profit of ¥0.50B, achieving a margin of 35.5%. This segment demonstrates viable unit economics despite smaller scale (39.1% of revenue). The margin differential of 237.9 percentage points between segments highlights severe portfolio imbalance. Separator's negative margin reflects excess capacity, unfavorable pricing, or structural cost disadvantages requiring immediate remediation. Ion Exchange Membrane's strong profitability suggests potential for resource reallocation, though scale limitations constrain near-term contribution. Segment assets totaled ¥50.77B (Separator ¥45.68B, Ion Exchange ¥5.09B), with Separator representing 90.0% of segment assets while generating substantial losses. Depreciation of ¥1.53B (Separator ¥0.91B, Ion Exchange ¥0.62B) indicates continued asset utilization despite revenue decline.
[Profitability] ROE -30.5% reflects severe earnings deterioration against equity base of ¥40.93B. Operating margin -135.5% indicates fundamental business model stress with costs exceeding revenue. Net profit margin -343.4% incorporates equity method losses and extraordinary items. The company faces structural profitability challenges requiring operational restructuring. [Cash Quality] Cash and deposits ¥0.27B provide minimal liquidity buffer. Short-term debt coverage ratio 0.04x (cash/short-term debt of ¥6.67B) signals acute refinancing pressure. Operating CF of ¥0.75B represents 10.2% conversion from prior ¥4.01B, indicating weakened cash generation. Operating CF/Net Income ratio of -0.06x shows accounting losses exceed cash outflows, though negative earnings limit interpretability. [Investment Efficiency] Asset turnover 0.07x (revenue ¥3.63B/average assets ¥56.04B) reflects severe revenue contraction against asset base. Investment securities of ¥34.62B (66.6% of assets) dominate balance sheet, suggesting holding company characteristics. Construction in progress ¥3.21B (27.2% of PPE) indicates incomplete capital projects potentially contributing to underutilization. [Financial Health] Equity ratio 78.7% (¥40.93B equity/¥52.00B assets) appears strong but masks liquidity stress. Current ratio 45.1% (¥3.86B/¥8.57B) falls critically below 100% threshold, indicating working capital deficit of ¥4.70B. Debt-to-equity 0.19x (interest-bearing debt ¥7.85B/equity ¥40.93B) suggests manageable leverage, though short-term debt concentration creates maturity mismatch risk. Net asset value per share ¥707.26 declined from prior ¥902.47, reflecting retained earnings erosion to ¥-28.16B.
Operating CF of ¥0.75B represents a sharp 81.4% decline from prior ¥4.01B, with OCF/Net Income ratio of -0.06x indicating cash generation substantially exceeds accounting losses due to non-cash equity method losses (¥6.33B) and depreciation (¥1.53B). Subtotal operating CF before working capital was ¥1.13B, reflecting adjustments for impairment (¥0.58B) and equity method losses. Working capital movements contributed ¥4.43B through inventory reduction of ¥1.22B (finished goods declined from ¥1.81B to ¥0.63B, a 65.2% decrease suggesting demand-driven destocking), trade receivables decline of ¥2.94B (improving collections amid revenue contraction), and payables increase of ¥0.13B. Interest paid of ¥0.33B and minimal tax payments of ¥0.05B completed operating activities. Investing CF of ¥-0.73B comprised CapEx of ¥1.14B offset by proceeds from asset sales of ¥0.80B and subsidiary stock sales of ¥0.25B, indicating capital deployment discipline amid financial stress. The CapEx/D&A ratio of 0.74x suggests reduced reinvestment below depreciation levels. Financing CF of ¥0.02B reflected gross short-term borrowing increases of ¥1.22B and long-term loan proceeds of ¥0.68B, offset by short-term debt repayments of ¥0.62B and long-term loan repayments of ¥1.40B, indicating active liability management. Subsidiary deconsolidation reduced cash by ¥0.48B. Free cash flow of ¥0.02B (OCF ¥0.75B minus investing ¥0.73B) essentially reached zero, eliminating capacity for discretionary distributions. The 84.9% short-term liability ratio amplifies refinancing urgency.
Ordinary loss of ¥11.41B versus operating loss of ¥4.92B reveals ¥6.49B in net non-operating charges, primarily equity method investment losses of ¥6.33B representing 55.5% of ordinary loss magnitude. These losses from affiliated investments indicate portfolio-wide distress extending beyond core operations. Non-operating income of ¥0.34B included FX gains of ¥1.01B and subsidy income of ¥0.11B, partially offsetting non-operating expenses of ¥6.83B which comprised equity method losses, interest expense of ¥0.24B, and FX losses of ¥0.19B. The ¥1.01B FX gain versus ¥0.19B FX loss suggests hedging or translation timing effects. Non-operating items represent 178.9% of revenue, fundamentally altering earnings composition. Extraordinary losses of ¥1.05B (impairment ¥0.58B, subsidiary stock sale loss ¥0.47B) are non-recurring but material at 28.9% of revenue. Comprehensive income of ¥-9.18B versus net loss of ¥12.47B shows ¥3.29B in OCI gains, primarily share of OCI from equity method investments of ¥4.11B offsetting FX translation adjustment of ¥-0.82B. This ¥4.11B OCI contribution from equity investments contrasts sharply with ¥6.33B P&L equity method losses, suggesting portfolio valuation support despite operating distress. Operating CF of ¥0.75B against net loss of ¥12.47B indicates cash losses substantially below accounting losses, primarily due to non-cash equity method charges. However, the 81.4% YoY OCF decline signals deteriorating cash generation quality. Accruals analysis shows working capital contributed ¥4.43B to OCF through asset liquidation (inventory, receivables), representing one-time balance sheet optimization rather than sustainable earnings quality.
Full-year FY2027 forecast projects revenue ¥6.00B (+65.2% YoY), operating loss ¥2.40B (improved from ¥4.92B), ordinary loss ¥4.40B (improved from ¥11.41B), and net loss ¥4.40B (improved from ¥12.47B). The forecast implies continued losses despite revenue recovery, with operating margin improving to -40.0% from -135.5% and net margin to -73.3% from -343.4%. Revenue guidance of ¥6.00B represents partial recovery toward historical levels but remains 80.7% below prior year's ¥31.05B baseline. The projected operating loss reduction to ¥2.40B suggests gross margin improvement expectations, requiring either pricing recovery, cost reduction, or favorable product mix. Ordinary loss forecast of ¥4.40B implies continuing equity method investment losses of approximately ¥2.00B (calculated as operating loss ¥2.40B to ordinary loss ¥4.40B gap), though reduced from current ¥6.33B, indicating assumed affiliate recovery. EPS forecast of ¥-79.73 based on projected net loss and average shares outstanding. Dividend forecast remains ¥0.00, consistent with loss position and liquidity constraints. The forecast assumes business model stabilization but not profitability restoration within the fiscal year. Key assumptions likely include Separator segment demand recovery, Ion Exchange Membrane growth, and affiliate investment stabilization, though specific guidance notes reference supplementary materials not provided in dataset. Without order backlog disclosure, forward revenue visibility remains limited to management projections.
Annual dividend ¥0.00 per share for FY2026, unchanged from prior year ¥0.00. Payout ratio is not applicable given net loss position. The company forecasts continued zero dividend for FY2027. No share buyback activities reported during the period. Total shareholder return ratio is 0.0% reflecting absence of both dividends and buybacks. The dividend suspension aligns with financial distress indicated by ¥12.47B net loss, negative retained earnings of ¥28.16B, and critical liquidity position (current ratio 45.1%). Free cash flow of ¥0.02B provides no capacity for distributions. Treasury stock holdings remained stable at 0.30M shares (¥0.34B), representing 0.5% of issued shares, with no repurchase activity. Capital allocation priorities necessarily focus on operational restructuring, liability management, and liquidity preservation rather than shareholder distributions. Dividend resumption would require sustained return to profitability, positive free cash flow generation, and improved balance sheet strength, none of which are forecast for FY2027. The zero-payout policy is expected to persist until structural profitability is restored.
Liquidity crisis risk: Current ratio of 45.1% with cash of ¥0.27B against short-term debt of ¥6.67B creates refinancing urgency. The 84.9% short-term liability concentration and cash coverage ratio of 0.04x indicate potential inability to meet near-term obligations without additional financing. Working capital deficit of ¥4.70B requires immediate resolution through asset liquidation, liability restructuring, or capital injection. Equity method investment portfolio distress: ¥6.33B in equity method losses represent 55.5% of ordinary loss and indicate fundamental challenges at affiliated entities. Investment securities of ¥34.62B (66.6% of total assets) carry valuation risk if affiliate distress persists. Share of OCI from equity method of ¥4.11B suggests unrealized gains supporting book value, but realization uncertainty remains high. Continued affiliate losses would perpetuate consolidated unprofitability regardless of operating improvements. Separator business structural challenges: The core Separator segment generated ¥2.21B revenue (60.9% of total) with operating loss of ¥4.48B (margin -202.4%), indicating fundamental business model failure. Customer concentration shifted from Samsung SDI (¥28.45B prior year) to W-SCOPE CHUNGJU at ¥1.87B, suggesting market share loss or contractual changes. Impairment loss of ¥0.58B reflects asset write-downs. Without demand recovery, pricing improvement, or radical cost restructuring, Separator segment threatens continued losses. Construction in progress of ¥3.21B (27.2% of PPE) may represent stranded capital if demand does not materialize.
[Industry Position] (Reference - Proprietary Analysis)
The company's financial metrics indicate severe underperformance relative to manufacturing sector medians. Revenue Growth of -88.3% falls drastically below industry median of +3.7% (IQR -0.4% to +9.4%), representing an extreme outlier driven by structural business disruption rather than cyclical factors. Operating Margin of -135.5% versus industry median of 7.7% (IQR 4.5% to 12.2%) and Net Profit Margin of -343.4% versus industry median of 5.2% (IQR 2.3% to 8.2%) place the company in profound distress territory. ROE of -30.5% compares unfavorably to industry median of 6.3% (IQR 3.2% to 9.9%), reflecting both negative earnings and equity base erosion. ROA of -20.4% significantly trails industry median of 3.9% (IQR 1.7% to 5.9%). Asset Turnover of 0.07x falls far below industry median of 0.76x (IQR 0.61 to 0.90), indicating severe revenue generation inefficiency against the asset base.
Equity Ratio of 78.7% substantially exceeds industry median of 60.7% (IQR 46.2% to 75.0%), appearing strong but primarily reflecting investment securities concentration rather than operational strength. Current Ratio of 45.1% falls critically below industry median of 2.66x (IQR 1.90x to 4.00x), ranking in the bottom percentile for liquidity. Cash Conversion Ratio calculation is distorted by negative earnings, but Operating CF of ¥0.75B against industry context suggests severe cash generation weakness. The company's inventory turnover and working capital metrics reflect business contraction dynamics incomparable to stable industry operations. Financial Leverage of 1.27x falls below industry median of 1.61x (IQR 1.33 to 2.09), though this reflects investment holding structure rather than operational efficiency. Dividend Payout Ratio is not applicable versus industry median of 0.33 given zero distributions.
The company operates in an extreme distress scenario fundamentally disconnected from normal industry performance parameters, requiring evaluation through turnaround and restructuring frameworks rather than conventional peer comparison. Industry benchmarks primarily serve to quantify the magnitude of operational and financial deterioration requiring remediation.
※ Industry: Manufacturing (243 companies), Comparison: FY2025 fiscal periods, Source: Proprietary analysis
Structural business model failure requiring comprehensive restructuring: The combination of -88.3% revenue decline, -135.5% operating margin, and ¥6.33B equity method losses indicates systematic rather than cyclical challenges. The Separator segment's -202.4% margin demonstrates fundamental unviability at current scale and cost structure, while Ion Exchange Membrane's 35.5% margin suggests portfolio rebalancing potential. Management's FY2027 guidance projecting continued losses despite 65.2% revenue recovery acknowledges multi-year restructuring requirements. Investors should monitor progress on Separator segment rationalization, affiliate investment stabilization, and Ion Exchange scaling as primary turnaround indicators.
Critical liquidity position creating binary refinancing risk: Current ratio of 45.1%, cash coverage of 0.04x against ¥6.67B short-term debt, and 84.9% short-term liability concentration create immediate refinancing necessity. Free cash flow of ¥0.02B provides no buffer, while working capital contributed ¥4.43B through one-time asset liquidation unlikely to repeat. The company requires either liability term extension, additional borrowing facilities, asset sales, or equity injection within fiscal year. Successful refinancing would provide operational runway; failure could trigger insolvency. Near-term financial announcements regarding credit facilities, parent support, or strategic partnerships merit close attention.
Investment securities portfolio concentration as primary value driver and risk: ¥34.62B in investment securities (66.6% of assets) with ¥4.11B in share of OCI suggests significant unrealized value, yet ¥6.33B equity method losses indicate operating distress at affiliates. Book value per share of ¥707.26 heavily depends on investment portfolio realizable value. The apparent disconnect between P&L equity method losses and OCI gains suggests timing differences, portfolio composition, or valuation methodology warranting detailed disclosure review. Investment thesis increasingly centers on affiliate recovery and portfolio realization rather than standalone operating performance. Investors should demand transparency regarding affiliate financial condition, strategic options for investment portfolio, and potential monetization timelines to validate asset-based valuation support.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.